Phase 2 clinical trial of the alternative therapy with osimertinib and afatinib for treatment-naive advanced NSCLC with EGFR mutation. (Alt trial) (WJOG10818L) (Alt trial (WJOG10818L))
Latest Information Update: 16 Jun 2022
Price :
$35 *
At a glance
- Drugs Afatinib (Primary) ; Osimertinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Alt trial Alt trial (WJOG10818L)
- Sponsors Nippon Boehringer Ingelheim
- 01 Jun 2022 Results published in the Lung Cancer
- 06 Mar 2021 New trial record
- 31 Jan 2021 Primary endpoint (One-year progression-free survival (PFS) rate) was not met as per the results presented at the 2020 World Conference on Lung Cancer.